Intensive Care Quality Indicators Dashboard Using Observational Medical Outcomes Partnership Common Data Model

Archive ouverte

Delange, Boris | Bouzillé, Guillaume | Popoff, Benjamin | Pierre-Jean, Morgane | Maamar, Adel | Cuggia, Marc

Edité par CCSD ; IOS Press -

International audience. This paper presents the development of a visualization dashboard for quality indicators in intensive care units (ICUs), using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The dashboard enables the user to visualize quality indicator data using histograms, pie charts and tables. Our project uses the OMOP CDM, ensuring a seamless implementation of our dashboard across various hospitals. Future directions for our research include expanding the dashboard to incorporate additional quality indicators and evaluating clinicians’ feedback on its effectiveness.

Suggestions

Du même auteur

How to Accurately Detect Renal Replacement Therapy Weaning in Intensive Care: Data Quality and Standardization Considerations for the OMOP Common Data Model

Archive ouverte | Popoff, Benjamin | CCSD

International audience. This study assesses the effectiveness of the Observational Medical Outcomes Partnership common data model (OMOP CDM) in standardising Continuous Renal Replacement Therapy (CRRT) data from int...

Applying Machine Learning for Prescriptive Support: A Use Case with Unfractionated Heparin in Intensive Care Units

Archive ouverte | Delange, Boris | CCSD

International audience. Continuous unfractionated heparin is widely used in intensive care, yet its complex pharmacokinetic properties complicate the determination of appropriate doses. To address this challenge, we...

Anti-factor Xa during unfractionated heparin therapy in critically ill patients: Development of prediction models using machine learning

Archive ouverte | Delange, Boris | CCSD

International audience. Objective: Unfractionated heparin (UFH) is a widely used therapy in intensive care units (ICUs) and is associated with an increased risk of serious adverse events or death if the therapeutic ...

Chargement des enrichissements...